TY  - GEN
AU  - Ding,X
AU  - Faber,K
AU  - Shi,Y
AU  - McKnight,J
AU  - Dorshorst,D
AU  - Ware,J A
AU  - Dean,B
TI  - Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS
SN  - 1873-264X
PY  - 2017///0509
KW  - Antineoplastic Agents
KW  - analysis
KW  - Area Under Curve
KW  - Calibration
KW  - Chromatography, Liquid
KW  - methods
KW  - Chromatography, Reverse-Phase
KW  - Drug Stability
KW  - Drug Storage
KW  - Half-Life
KW  - Humans
KW  - Imidazoles
KW  - Linear Models
KW  - Oxazepines
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Reproducibility of Results
KW  - Solid Phase Extraction
KW  - Tandem Mass Spectrometry
KW  - Temperature
KW  - Time Factors
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Validation Study
UR  - https://doi.org/10.1016/j.jpba.2016.04.030
ER  -